Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00206024 · ClinicalTrials.gov registry record · Phase 4

Acid-Associated Heartburn Symptoms and Dose of Esomeprazole

A Phase 4 study of Heartburn, sponsored by AstraZeneca.

Completed
Registry status
Phase 4
Development phase
330
Enrollment target
20
Study locations

NCT00206024 is a Phase 4 study of Heartburn that has completed, run by AstraZeneca. The registered enrollment target is 330 participants, below the 383-participant average among 9 other Heartburn trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00206024, a Phase 4 study of Heartburn, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 4
Development phase
330 participants
Enrollment target
20
Study locations

Study Summary

This is a multi-center, double-blind, parallel-group, randomized, proof of concept trial to investigate the relationship between dose of esomeprazole magnesium and acid-associated heartburn symptoms during 4 weeks of treatment. The safety and tolerability of esomeprazole magnesium in doses up to 40 mg BID will also be assessed.

Conditions Studied

Heartburn

Interventions

  • DRUG Esomeprazole magnesium (Nexium)

Study Locations (20)

Florida

  • Research Site - DeLand
  • Research Site - Miami
  • Research Site - New Smyrna Beach
  • Research Site - Tampa
  • Research Site - Zephyrhills

California

  • Research Site - Anaheim
  • Research Site - Orange
  • Research Site - San Diego

Maryland

  • Research Site - Annapolis
  • Research Site - Baltimore
  • Research Site - Hollywood

New Jersey

  • Research Site - Hackensack
  • Research Site - Vineland

Arizona

  • Research Site - Tucson

District of Columbia

  • Research Site - Washington D.C.

Georgia

  • Research Site - Atlanta

Illinois

  • Research Site - Chicago

Trial Details

FieldValue
Enrollment Target 330 participants
Start Date 2004-11
Est. Completion 2005-07
Phase Phase 4

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00206024

The ClinicalTrials.gov registry entry for NCT00206024 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 383-participant average among 9 other Heartburn trials with a reported enrollment target (14% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heartburn appearing as the primary indexed condition, and to 1 intervention - of which Esomeprazole magnesium (Nexium) is the first listed.

NCT00206024 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Maryland.

Frequently Asked Questions

What is clinical trial NCT00206024 about?

NCT00206024 is a clinical study titled "Acid-Associated Heartburn Symptoms and Dose of Esomeprazole". This is a multi-center, double-blind, parallel-group, randomized, proof of concept trial to investigate the relationship between dose of esomeprazole magnesium and acid-associated heartburn symptoms during 4 weeks of treatment. The safety and tolerability of esomeprazole magnesium in doses up to 40 ...

What is the current status of trial NCT00206024?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 330 participants. The study started on 2004-11. Estimated completion is 2005-07.

What conditions does trial NCT00206024 study?

This clinical trial studies the following conditions: Heartburn.

What interventions are being tested in trial NCT00206024?

The interventions under investigation include: Esomeprazole magnesium (Nexium) (DRUG).

Who is sponsoring clinical trial NCT00206024?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00206024 being conducted?

This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heartburn

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heartburn

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.